Technology Insight: imaging neurodegeneration in Parkinson's disease

Currently, the clinical diagnosis of Parkinson's disease (PD) can be problematic, particularly at the early stages of the disease when the full spectrum of symptoms and signs might not yet be manifest. In addition, the mechanisms that underlie the nonmotor complications of PD, such as dementia and depression, are poorly understood, despite the fact that these symptoms largely determine the patient's quality of life at the end stage of the disease. This article reviews the latest advances in structural and functional imaging that have provided important insights into the structural, pathophysiological and pharmacological changes associated with PD. The contribution of inflammatory processes to the pathology of PD is discussed, as are the various possible mechanisms that lead to coexistent dementia and depression.

[1]  C. Summerfield,et al.  Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia , 2005, Journal of Neurology.

[2]  Clinical and [ 18 F ] dopa PET findings in early Parkinson ' s disease , .

[3]  David J Brooks,et al.  Plasticity of the nigropallidal pathway in Parkinson's disease , 2003, Annals of neurology.

[4]  Nora Turjanski,et al.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.

[5]  Andrew J Lees,et al.  Diffusion‐weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple‐system atrophy from progressive supranuclear palsy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[6]  L. Deecke,et al.  [123I]β‐CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration , 2000, Movement disorders : official journal of the Movement Disorder Society.

[7]  D R Rajput,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[8]  David Eidelberg,et al.  Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging , 2007, Movement disorders : official journal of the Movement Disorder Society.

[9]  W. A. White Stages of Development. , 1919 .

[10]  T. Ishikawa,et al.  The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  Nicola Pavese,et al.  Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. , 2002, Brain : a journal of neurology.

[12]  D J Burn,et al.  Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study , 1997, Annals of neurology.

[13]  M. Skalej,et al.  Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy , 1999, Annals of neurology.

[14]  L. Minati,et al.  Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. , 2007, AJNR. American journal of neuroradiology.

[15]  I. McKeith,et al.  Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging , 2005, Movement disorders : official journal of the Movement Disorder Society.

[16]  V. Dhawan,et al.  Metabolic correlates of levodopa response in Parkinson’s disease , 2001, Neurology.

[17]  R. Hilker,et al.  Dementia in Parkinson disease , 2005, Neurology.

[18]  Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation , 2005, Neurology.

[19]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[20]  D J Brooks,et al.  Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[21]  S. Minoshima,et al.  In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.

[22]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[23]  J. Hogg Magnetic resonance imaging. , 1994, Journal of the Royal Naval Medical Service.

[24]  N. Bohnen,et al.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.

[25]  D. Brooks,et al.  Extrastriatal monoamine neuron function in Parkinson’s disease: An 18F-dopa PET study , 2008, Neurobiology of Disease.

[26]  D J Brooks,et al.  Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[27]  G Becker,et al.  Relationship of substantia nigra echogenicity and motor function in elderly subjects , 2001, Neurology.

[28]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[29]  Makoto Sawada,et al.  Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.

[30]  Jan Booij,et al.  The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.

[31]  Nick C Fox,et al.  Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations , 2006, Movement disorders : official journal of the Movement Disorder Society.

[32]  Christine Klein,et al.  Brain parenchyma sonography detects preclinical parkinsonism , 2004, Movement disorders : official journal of the Movement Disorder Society.

[33]  Zuzana Walker Dementia with Lewy bodies , 2001 .

[34]  I. McKeith,et al.  Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[35]  Won Yong Lee,et al.  Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  D. Brooks Functional imaging in relation to parkinsonian syndromes , 1993, Journal of the Neurological Sciences.

[37]  E. Tolosa,et al.  Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes , 2004, Movement disorders : official journal of the Movement Disorder Society.

[38]  N. Bohnen,et al.  Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease , 2005, Neuroscience Letters.

[39]  Daniela Berg,et al.  Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.

[40]  D E Kuhl,et al.  Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia , 1999, Neurology.

[41]  L. Golbe The genetics of Parkinson's disease: A reconsideration , 1990, Neurology.

[42]  Akinori Nakamura,et al.  Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. , 2002, Brain : a journal of neurology.

[43]  H. Berendse,et al.  Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.

[44]  Anna Barnes,et al.  FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.

[45]  J R Moeller,et al.  Metabolic changes following subthalamotomy for advanced Parkinson's disease , 2001, Annals of neurology.

[46]  V J Cunningham,et al.  Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. , 2000, Brain : a journal of neurology.

[47]  David J. Brooks,et al.  A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson’s disease , 2001, Neurology.

[48]  Z Walker,et al.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.

[49]  J O Rinne,et al.  Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. , 2000, Archives of neurology.

[50]  Klaus Fassbender,et al.  Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. , 2006, Brain : a journal of neurology.

[51]  D. Brooks,et al.  Tremor in Parkinson’s disease and serotonergic dysfunction , 2003, Neurology.

[52]  W. Oertel,et al.  Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. , 2004, Brain : a journal of neurology.

[53]  J. Patterson,et al.  Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging , 2006, Nuclear medicine communications.

[54]  Thomas Hummel,et al.  Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT , 2004, Movement disorders : official journal of the Movement Disorder Society.

[55]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[56]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[57]  T Turner,et al.  Structural changes. , 1991, Nursing times.

[58]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[59]  N. Mauras Growth Hormone Therapy in the Glucocorticosteroid-Dependent Child: Metabolic and Linear Growth Effects , 2002, Hormone Research in Paediatrics.

[60]  D Oakes,et al.  Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease , 2003, Experimental Neurology.

[61]  E. Yoshikawa,et al.  Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.

[62]  E. Tolosa,et al.  Role of DAT‐SPECT in the diagnostic work up of Parkinsonism , 2007 .

[63]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[64]  Francesco Fera,et al.  Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. , 2006, Brain : a journal of neurology.

[65]  C. Rowe,et al.  II.P13 Amyloid load in Parkinson's Disease Dementia (PDD) and Lewy Body Dementia (LBD) measured with 11C-PIB PET , 2006 .

[66]  C. Summerfield,et al.  Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. , 2005, Archives of neurology.

[67]  Nicola Pavese,et al.  Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. , 2004, Brain : a journal of neurology.

[68]  M Hutchinson,et al.  Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. , 2000, AJNR. American journal of neuroradiology.

[69]  Daniela Berg,et al.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.

[70]  C Kremser,et al.  Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.

[71]  Karl Herholz,et al.  The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans , 2002, Neuroscience Letters.

[72]  K. Uğurbil,et al.  Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts , 2007, Movement disorders : official journal of the Movement Disorder Society.

[73]  Chi-Shing Zee,et al.  Magnetic Resonance Imaging-Based Volumetric Analysis of Basal Ganglia Nuclei and Substantia Nigra in Patients with Parkinson’s Disease , 2006, Neurosurgery.

[74]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[75]  I. McKeith,et al.  Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease , 2004, Neurology.

[76]  P. Amarenco,et al.  Tremor in Parkinson's disease and serotonergic dysfunction An 11 C-WAY 100635 PET study , 2003 .

[77]  David Oakes,et al.  (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. , 2004, Archives of neurology.

[78]  Daniela Berg,et al.  Five‐year follow‐up study of hyperechogenicity of the substantia nigra in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.